ArticleThoracic cancer2025
Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Frequency and Prognostic Impact of Local Ablation Therapy for Oligoprogression in Non-Small Cell Lung Cancer.Thoracic cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDuring the systemic treatment of patients with non-small cell lung cancer (NSCLC), oligoprogression (OP), a condition in which most lesions remain controlled while a few progress or develop, has recently attracted attention. Traditionally, systemic therapy is continued after disease progression; however, advancements in local ablation therapy (LAT), such as radiotherapy and surgery, have demonstrated clinical efficacy in patients with OP. The characteristics of patients who may benefit from LAT or their genetic background remain unclear. This study evaluated the frequency, clinicopathological characteristics, and efficacy of LAT in the treatment of OP.
methodsA retrospective review was conducted of 510 patients with NSCLC who experienced disease progression after systemic therapy.
resultsOverall, 106/510 (23.6%) patients exhibited OP; among these, six patients who received only the best supportive care after OP were excluded. Systemic therapy alone was administered to 79 patients (79.0%), while 21 (21.0%) received LAT. Median local progression-free survival was numerically longer in the LAT group than in the systemic therapy-only group (8.3 and 6.7 months, respectively; p = 0.38). In addition, overall survival was also numerically longer in the LAT group than in the systemic therapy-only group (78.1 and 55.1 months, respectively; p = 0.57). Ribonucleic acid sequencing revealed an increase in extracellular matrix-related gene expression after OP, providing potential molecular insights.
conclusionsAlthough this study found no significant prognostic benefit of LAT in patients with OP, future research integrating clinical and molecular data may identify patients most likely to benefit from LAT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.